Santen, Inc.

29 articles with Santen, Inc.

• Santen Announces U.S. FDA Filing Acceptance of New Drug Application (NDA) for Cyclosporine Topical Ophthalmic Emulsion, 0.1% for the Treatment of Severe Vernal Keratoconjunctivitis in Patients Ages 4-18

  10/26/2020

   Santen Inc., the U.S. subsidiary of Santen Pharmaceutical Co., Ltd. (hereinafter, Santen), a global company focused exclusively on ophthalmology, today announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for cyclosporine topical ophthalmic emulsion, 0.1% for the treatment of se

• 

  How COVID-19 is Affecting Clinical Trials and Drug Supplies from Biotech Bay Companies

  6/5/2020

  Check out this article for the impacts that Biotech Bay companies are experiencing due to COVID-19.

• Santen Inc. Announces Appointment of Tatsuya Kaihara as Corporate Officer and Head of North America Business of Santen Pharmaceutical

  4/1/2020

  Santen Inc., a U.S. subsidiary of Santen Pharmaceutical Co., Ltd., a global company focused exclusively on ophthalmology, today announced the appointment of Tatsuya Kaihara as Corporate Officer and Head of North America Business of Santen Pharmaceutical.

• Santen and TRACON Discontinue Development of DE-122 for Wet Age-Related Macular Degeneration

  3/9/2020

  Santen Pharmaceutical Co., Ltd. (Head Office: Osaka; hereinafter, “Santen”) and TRACON Pharmaceuticals, Inc. (Head Office: San Diego, CA; hereinafter, “TRACON”) today announced the discontinuation of the development of DE-122 for the treatment of wet age-related macular degeneration (wAMD) following the review of recently obtained top-line data from the Phase 2a AVANTE clinical study. The Phase 2a AVANTE clinical study is a rando

• Santen to Conduct Activities to Raise Awareness on Importance of Early Detection and Treatment of Glaucoma during World Glaucoma Week (March 8-14, 2020)

  3/5/2020

  Santen Pharmaceutical Co., Ltd. (Head Office: Osaka; Chairman and CEO: Akira Kurokawa; hereinafter, “Santen”) announced today that it will support glaucoma awareness-raising activities to be conducted around the world from March 8 to 14, 2020.

• Santen and Verily Establish Joint Venture to Develop and Commercialize Unique Ophthalmic Devices

  2/4/2020

  Santen Pharmaceutical Co., Ltd. (Head office: Osaka, hereinafter “Santen”) and Verily, an Alphabet company, announced the establishment of a joint venture※ focused on applying microelectronics and scalable digital technologies to ophthalmology.

• Santen Announces Topline Pivotal Data for DE-128 (MicroShunt) Demonstrating Reductions in Intraocular Pressure and Medication Use in Patients with Mild, Moderate and Severe Primary Open-Angle Glaucoma

  8/30/2019

  Santen Pharmaceutical Co., Ltd. (“Santen” TSE: 4536) today announced the results of INN-005, a prospective, randomized, controlled, single-masked, multicenter study to assess the safety and effectiveness of DE-128 (MicroShunt) standalone, without concomitant cataract extraction.

• Santen Hosts Event to Raise Public Awareness of Importance of Continued Glaucoma Treatment Prior to Sponsoring World Glaucoma Week in March

  1/30/2019

  As part of its efforts to raise public awareness of glaucoma, Santen Pharmaceutical Co., Ltd., based in Osaka, will sponsor glaucoma awareness-raising activities to be conducted around the world during the World Glaucoma Week, from Sunday, March 10, to Saturday, March 16, 2019.

• Santen Expands Research and Development Leadership Team with Additions of Reza M. Haque, MD, PhD and Peter Sallstig, MD, MBA

  11/15/2018

  Reza M. Haque, MD, PhD, has been appointed as Senior Vice President, Global Research and Development Strategy, and Peter Sallstig, MD, MBA, has been appointed as Senior Vice President, Global Product Development.

• 

  BioSpace Movers and Shakers Nov. 5

  11/5/2018

  Biopharma companies make key appointments to fill leadership positions. Let's take a look!

• Santen Announces Initiation of Phase 3 Clinical Development Program (SPECTRUM) in the United States Evaluating Omidenepag Isopropyl (DE-117) for the Treatment of Glaucoma or Ocular Hypertension

  10/22/2018

  Pivotal Phase 3 development program (SPECTRUM) in the United States, evaluating the investigational use of omidenepag isopropyl (DE-117), a selective agonist for the prostanoid receptor EP2, for the treatment of glaucoma or ocular hypertension (OHT).

• Santen Presents Phase I/II Data on DE-122 (Carotuximab) in Patients With Refractory Wet Age-Related Macular Degeneration

  2/12/2018

  No serious adverse events were reported.

• Santen Receives CRL Letter From FDA for Intravitreal Sirolimus (DE-109)

  12/21/2017

  The CRL indicates that the FDA is unable to approve the application in its present form and requests additional substantiating evidence to demonstrate efficacy of IVT sirolimus in the treatment of noninfectious uveitis of the posterior segment.

• Santen Announces U.S. FDA Filing Acceptance Of New Drug Application (NDA) For Intravitreal Sirolimus (DE-109) In The Treatment Of Non-Infectious Uveitis Of The Posterior Segment

  4/25/2017

• Santen—An Overlooked Play On An Overlooked Space

  3/10/2017

• Santen And twoXAR Announce Strategic Research Collaboration To Discover New Glaucoma Treatments

  2/23/2017

• Santen, Inc. Launches IKERVIS - The First And Only Ciclosporin Eye Drops Licensed In The UK, On 27th July 2015

  7/24/2015

• SANTEN Launches TAPTIQOM Preservative-Free Fixed Combination Eye Drops In The UK

  7/10/2015

• Clearside Biomedical And Santen, Inc. Announce Research Collaboration In Glaucoma

  5/4/2015

• European Medicines Agency Accepts Santen, Inc.'s Marketing Application Filing For Intravitreal Sirolimus For The Treatment Of Noninfectious Uveitis Of The Posterior Segment

  3/2/2015